Abstract Dyspnoea remains a remarkable clinical problem and a therapeutic challenge, mainly in chronic respiratory conditions.This study investigated the potential effects of steroids on dyspnoea sensation regardless of their pulmonary anti-inflammatory actions. Sixteen healthy men (mean age + SD = 22.5+1.6 years) developed uncomfortable breathing by the use of inspiratory resistors (loads of 0, 7,14 and 21cm H 2 O/l/s) and breathholding 6 h after taking 40 mg of prednisone (Pred) or placebo (Plac).Respiratory discomfort during breathing with loads was evaluated with a100 mm visual analog scale. The maximum voluntary apnoea time did not differ between the prednisone and placebo days (Plac= 96+11.8 s Â Pred=105+12.2 s) and prednisone did not influence the dyspnoea sensation induced by different inspiratory loads (0 cm H 2 O/l/s: Pred=2.8 mm Â Plac=1.9 mm; 7 cm H 2 O/l/s: Pred=18.3 mm Â Plac=18.6 mm; 14 cm H 2 O/l/s; Pred=33.0 mm Â Plac=34.1mm; 21cm H 2 O/l/s: Pred=48.1mm Â Plac=49.6 mm).Prednisone intake was associated with a significant increase in minute ventilation during breathing with no inspiratory loads (Pred=11.91+1.28 l/min-Â Plac=9.95+0.86 l/min). Although steroids certainly may improve respiratory conditions due to anti-inflammatory actions, available evidence does not support any specific beneficial effect of these drugs on the perception of dyspnoea itself. r
Dyspnoea is one of the most common complaints among patients with cardiorespiratory diseases and is often the reason why a person seeks medical care.The presence of unpleasant respiratory sensations is the most important symptom a¡ecting the quality of life in patients with chronic respiratory failure (1, 2) . Although our knowledge about the physiological mechanisms that generate the respiratory sensations has increased in the past two years, dyspnoea still remains a tremendous clinical problem and a therapeutic challenge (3) . An agent able to reduce dyspnoea without signi¢cant side-e¡ects would never be a substitute for speci¢c therapy directed at the underlying respiratory disorder, but could be useful, mainly when the condition is irreversible (4) .
Steroids are chemical agents with multiple physiological and therapeutic actions (5) . Cortisol release is an important metabolic component of the ¢ght or run response to stress conditions. In addition, we have observed in our clinical practice that some patients with chronic obstructive pulmonary disease (COPD) report improvement of their symptoms on oral prednisone, although pulmonary function parameters do not change. Therefore, we raised the hypothesis that steroids could have a bene¢cial e¡ect on dyspnoea sensation independent of their well-known pulmonary anti-in£ammatory actions.
The present study was designed to investigate the effects of oral prednisone vs placebo on respiratory sensations in a group of healthy volunteers who developed uncomfortable breathing by the use of inspiratory resistors and keeping voluntary apnoea.
MATERIAL AND METHODS

Subject
Sixteen non-smoking, healthy male volunteers participated in the study after giving informed consent. None of the subjects had respiratory symptoms, past pulmonary illnesses and all had a normal physical examination. Special care was taken to exclude subjects with a history of asthma or wheezing during childhood. Age ranged from19 to 25 years, with a mean + SD of 22.5+1.6 years. The study was approved by the Ethics Committee of Hospital das Cl|¤ nicas de Ribeira ì o Preto.
Methods
Study design: Dyspnoeic sensations were induced by breathholding and breathing with di¡erent inspiratory resistive loadings.The volunteers came to the pulmonary function laboratory three times. On the ¢rst day (D-l), they performed spirometry and dyspnoea tests in order to familiarize themselves with the maneuvers. On the second (D-2) and third days (D-3), they were medicated with placebo or with 40 mg of PO prednisone 6 h before the tests. Drug or placebo was administered at random and in a double-blind manner. All tests were performed around midday at least 2 days apart, and with the subjects breathing room air.
Spirometry: Basal pulmonary function data were obtained using a Pulmonet Godard spirometer. Procedures were performed according to American Thoracic Society recommendations (6) . Forced vital capacity (FVC), forced expiratory volume in the ¢rst second (FEV l ) and the middle curve forced expiratory £ow (FEF 25^75% ) were analyzed as predicted of normal values. The FEV 1 / FVC ratios were expressed as percentage values. The predicted normal values were based on Crapo et al. (7) .
Breathholding: When the volunteers arrived at the pulmonary function laboratory they received an explanation of the proceedings and, after a brief resting period, were asked to hold their breath at the total lung capacity level, the most they could. An observer employed a chronometer to measure the apnoea length, while the volunteers used hand signaling to indicate the beginning and the end of the breathholding period. The maximum voluntary apnea time was measured twice, at least 15 minutes apart, and the duration was expressed as seconds. The best value obtained between the two maneuvers was chosen for analysis.
Breathing with inspiratory loads: Each subject breathed through an oral one-way valve system during the experiment. A nose clip was placed to assure no air leaks. The valve expiratory port was connected to a Collins Multimodular Lung Analyzer (model 02303) in order to register the respiratory pattern and tidal volume with a graphic ink system. End-tidal carbon dioxide tension (PET-CO 2 ) was measured with a CO 2 analyzer through a port in the expiratory limb.The same equipment is ¢tted with a pulse oximeter that was connected to one ¢nger to continuously monitor the arterial oxygen saturation (DX 7100 ETCO 2 /SPO 2 reader, Dixtal, SP). An adjustable resistor device employed in respiratory muscle training (Treshold IMT s , Healthscan, NJ) was connected to the valve inspiratory limb in order to introduce variable respiratory loads. The volunteers were asked to breath in the system without the resistor device (0 load) and with loads 7,14 and 21cm H 2 O/l/s.The di¡erent loads were applied at random and in a blinded manner for the volunteers. The subjects breathed over a period of 2 min at each load and, at the end of the second minute, their respiratory parameters were recorded and they were asked to rate the degree of respiratory discomfort using a visual analog scale (VAS) (8) . The analogue scale consisted of a vertical 100 mm line with the number zero at the bottom and the number 100 at the top. The volunteers were instructed to consider zero as the indication of no respiratory sensation at all and100 a sensation that was intolerable.
Statistical analysis: Data are reported as means and standard error of the means (SEM). Comparisons of the measurements obtained with prednisone and placebo were made using the paired t-test or Wilcoxon non-parametric test. A P value o0.05, corrected for multiple comparisons, was considered to be signi¢cant. The mean maximum voluntary apnoea time did not di¡er between the prednisone and placebo days (Placebo = 96+11.8 s Â Prednisone = 105+12.2 s; Fig.1) .
RESULTS
All
Overall, prednisone did not led to changes in tidal volume, exhaled carbon dioxide levels or arterial oxygen saturation at any load, compared to placebo. Prednisone intake led to increases in respiratory rate and minute ventilation, but the only change that reached statistical signi¢cance was the elevation in respiratory rate under basal conditions (Table 1) .
The use of prednisone did not in£uence the mean dyspnoea sensation induced by di¡erent inspiratory loads either (Fig. 2) .
DISCUSSION
Some drugs have been explored as a means of alleviating dyspnoea in chronic respiratory conditions. Such medications could act presumably by altering perceptual sensitivity or by exerting respiratory depressive e¡ects (3, 4) . Examples of this type of agents are opiates and anxiolytics. In addition, there are also suggestions that oral indomethacin and inhaled furosemide may positively interfere with the mechanisms that give rise to breathlessness (9, 10) .
Corticosteroids are agents with multiple physiological e¡ects and of widespread use in medicine, particularly in the respiratory ¢eld (5) . Recent investigations with the use of positron emission tomography scans have showed activation of speci¢c areas of the brain in response to different dyspnoea-inducing stimuli (11, 12) . It is well known that steroids readily enter the central nervous system and control gene expression in nervous cells via binding to di¡erent intracellular receptors, which act as gene transcription factors (13) . In addition, several studies have suggested that steroids produced locally in the brain, the so-called neurosteroids, may regulate neuronal excitability and may in£uence physiologic phenomena such as sexual function, memory and response to stress (14) . However, until recently there were no studies speci¢-cally designed to evaluate a possible role for steroids in dyspnoea perception.
In a recent paper, Noseda et al. found that the administration of an IV bolus of 125 mg of methylprednisolone to 18 patients with asthma exacerbation did not reduce dyspnoea more than saline solution within a time course of 60 min (15) . However, the period of1h may be not long enough for a complete action of the drug on the CNS or on receptors potentialy involved in respiratory perception located in the airways mucosa. In addition, due to their strong anti-in£ammatory actions, the best way to investigate a potential anti-dyspnoea role for steroids some hours after their ingestion would be to induce unpleasant respiratory sensations in healthy volunteers with no known pulmonary diseases.
There are several potential methods to induce dyspnoea in experimental conditions including performing exercises, breathing hypercapnic gas mixtures, or the application of ventilatory restrains (16) . Previous papers have employed normal volunteers breathing in respiratory circuits with loads, and measurement of breathholding times as methods to investigate physiological aspects and potential drug treatments for dyspnoea (9, 12, 16) . Using the latter instruments Nishino et al. were able to demonstrate remarkable prolongations of the breathholding time and the period of no respiratory sensation after inhalation of furosemide (9) . These authors also showed a decrease in the degree of respiratory discomfort associated with breathing with inspiratory loads after furosemide inhalation in comparison to placebo. We employed similar methods for practical reasons. Furthermore, we could also investigate the steroid effects on dyspnoea generated by distinct mechanisms.
In the present investigation, the oral administration of 40 mg of prednisone 6 h before the studies did not significantly improve the breathholding time or the degree of respiratory discomfort induced by di¡erent inspiratory loads in a group of 16 healthy young volunteers, nor did it lead to important changes in respiratory physiological parameters. Prednisone intake was only associated with a statistically signi¢cant increase in minute ventilation during breathing in the circuit with no inspiratory loads. Considering that increases in ventilation are generally related to worsening in dyspnoea, this ¢nding may be interpreted as further evidence against a bene¢cial e¡ect of steroids on respiratory sensations.
In daily clinical practice, we have observed some patients with stable advanced COPD who are not able to taper o¡ oral steroids due to worsening respiratory symptoms. Sometimes subjects with end-stage pulmonary ¢brotic disorders also report less dyspnoea and improvement in well-being after a short trial of prednisone or methylprednisolone. In both situations, the subjective amelioration of symptoms is not correlated with pulmonary function or arterial blood gas improvements. Based on the present results, we believe that these reports may probably be the expression of a non-speci¢c action of steroids on the CNS leading to mood elevation and euphoria despite unchanged dyspnoea perception and pulmonary status (5) .However, it is worth to emphasize that this study did not evaluate the chronic or the multidose e¡ects of steroids on dyspnoea sensation. The administration of prednisone on higher doses or for longer periods of time might have yielded di¡erent results.
In conclusion, although steroids may certainly improve respiratory conditions due to their anti-in£ammatory actions, doctors should be aware that the available evidence does not support any speci¢c bene¢cial e¡ect of these drugs on the perception of dyspnoea itself.
